Development of Novel Paclitaxel-Loaded ZIF-8 Metal-Organic Framework Nanoparticles Modified with Peptide Dimers and an Evaluation of Its Inhibitory Effect against Prostate Cancer Cells

Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a metal-organic-framework-encapsulated drug delivery nanoparticle with paclitaxel (PTX) as a model drug, and further modified the synthesized peptide dimer (Di-PEG200...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 15; no. 7; p. 1874
Main Authors Zhao, Heming, Gong, Liming, Wu, Hao, Liu, Chao, Liu, Yanhong, Xiao, Congcong, Liu, Chenfei, Chen, Liqing, Jin, Mingji, Gao, Zhonggao, Guan, Youyan, Huang, Wei
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.07.2023
MDPI
Subjects
Analysis
Androgens
Apoptosis
Cancer
Cancer therapies
Care and treatment
Cell culture
Chemotherapy
Clinical medicine
Drug delivery systems
Drugs
Efficiency
Ions
metal-organic framework
Nanoparticles
NMR
Nuclear magnetic resonance
Paclitaxel
Particle size
peptide dimer
Peptides
Polypeptides
Porous materials
Prevention
Prostate cancer
Tumors
Vehicles
Zinc
Japan
China
Beijing China
United States > US
paclitaxel
prostate cancer
peptide dimer
metal-organic framework
Online AccessGet full text

Cover

More Information
Summary:Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a metal-organic-framework-encapsulated drug delivery nanoparticle with paclitaxel (PTX) as a model drug, and further modified the synthesized peptide dimer (Di-PEG2000-COOH) onto the surface of PTX@ZIF-8 to prepare a nanotargeted drug delivery system (Di-PEG@PTX@ZIF-8) for the treatment of prostate cancer. This study investigated the morphology, particle size distribution, zeta potential, drug loading, encapsulation rate, stability, in vitro release behavior, and cytotoxicity of this targeted drug delivery system, and explored the uptake of Di-PEG@PTX@ZIF-8 by human prostate cancer Lncap cells at the in vitro cellular level, as well as the proliferation inhibition and promotion of apoptosis of Lncap cells by the composite nanoparticles. The results suggest that Di-PEG@PTX@ZIF-8, as a zeolitic imidazolate frameworks-8-loaded paclitaxel nanoparticle, has promising potential for the treatment of prostate cancer, which may provide a novel strategy for the delivery system targeting prostate cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15071874